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The purpose of this study was to determine the effect of 
the antiarrhythmic drugs lidocaine and bretylium on the 
minimal energy requirement for transthoracic defibril•
lation-the defibrillation threshold. Closed chest dogs 
were anesthetized with chloralose or pentobarbital; lido•
caine was administered at varying rates for 2 hours and 
defibrillation threshold periodically redetermined. Sim•
ilar protocols were followed for bretylium. Serum lido•
caine levels from therapeutic to toxic ranges were ob•
tained, and up to a 60% (p < 0.05) increase in defi•
brillation threshold in the pentobarbital-anesthetized dogs 
was demonstrated. In chloralose-anesthetized dogs the 
lidocaine effect was modest, with only a 10 to 20% rise 
in defibrillation threshold (p = NS) despite similar in-
The antiarrhythmic drugs lidocaine and bretylium are widely 
administered to prevent or treat ventricular arrhythmias, 
usually in the setting of an acute myocardial infarction or 
other serious cardiac illness. Because these drugs are not 
completely effective, however. some patients inevitably de•
velop ventricular fibrillation despite the drugs and require 
immediate direct current countershock for defibrillation. Thus. 
many patients undergoing defibrillation have recently re•
ceived or are receiving lidocaine or bretylium. 
Two recent experimental studies (1.2) found that antiar•
rhythmic agents affected the minimal energy required for 
transthoracic defibrillation: lidocaine increased energy re•
quirements and bretylium decreased them. If these results 
are reproducible and apply to humans. they suggest that 
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creases in serum lidocaine levels. 
Thus, lidocaine increases the minimal energy require•
ments for transthoracic defibrillation, but this effect is 
in part anesthesia-related, indicating a lidocaine-pen•
tobarbital interaction. When phentolamine was admin•
istered to chloralose-anesthetized dogs receiving lido•
caine, defibrillation threshold rose 13% (p < 0.05); this 
suggests that alpha-adrenergic receptor blockade is at 
least in part the mechanism of the pentobarbital-lido•
caine interaction on defibrillation threshold. Bretylium 
with either anesthetic had no significant effect on defi•
brillation threshold. 
(J Am Coil CardioI1986;7:397-40S) 
patients who develop ventricular fibrillation while receiving 
lidocaine will require transthoracic shocks of higher energies 
to achieve defibrillation, whereas patients receiving bre•
tylium may require less energy than usual to defibrillate. 
However. these studies (1,2) were performed on small groups 
of dogs. only a single anesthetic was used and no plasma 
drug levels were reported to correlate with the effects on 
energy requirements. Furthermore, a recent study (3) could 
not demonstrate an effect of bretylium on defibrillation en•
ergy requirements. Because of these conflicting but poten•
tially important experimental observations. our purpose in 
this study was to assess the reproducibility of the earlier 
defibrillation observations in a larger number of animals, to 
correlate the effect of lidocaine on transthoracic defibrilla•
tion energy requirements with plasma levels and to deter•
mine whether the anesthetic agent used in the experiment 
would affect the results. 
Methods 
Experimental preparation. Mongrel dogs weighing 15 
to 25 kg were used. The dogs were anesthetized with either 
intravenous chloralose (100 mg/kg body weight) and ure•
thane (1.000 mg/kg) or intravenous pentobarbital (15 mg/kg); 
0735-1097/86/$350 
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supplemental anesthesia was given as necessary. The ani•
mals were intubated and ventilated using inspired room air 
with supplemental oxygen as necessary. Arterial blood gases 
were determined every 30 minutes and intravenous sodium 
bicarbonate was given or the ventilation rate was adjusted 
as necessary to maintain the pH and partial pressure of 
carbon dioxide (PC02) in a physiologic range. Polyurethane 
8F catheters were inserted into the brachial artery and passed 
retrograde to the left ventricle from pressure monitor•
ing. Heart rate was determined from an external electro•
cardiogram. 
Ventricular defibrillation threshold. Defibrillation 
threshold, the minimal shock energy required to defibrillate 
the heart during each of the conditions assessed, was de•
termined using a modification of the technique of Babbs et 
al. (4). A bipolar catheter was passed to the right ventricular 
apex, and ventricular fibrillation was initiated by delivering 
a 60 Hz, 2 to 10 V, 5 second duration train of rectangular 
electrical pulses by way of the catheter. Ventricular fibril•
lation was allowed to persist for 15 seconds. We then ad•
ministered an initial shock of 160 J (energy delivered into 
a standard 50 0 resistance), which is adequate to defibrillate 
most dogs weighing 15 to 25 kg. All shocks were given 
from electrode paddles placed over the cardiac apex on the 
shaved left chest and the corresponding location on the 
shaved right chest. Hewlett-Packard Redux paste, a low 
resistance electrode gel, was used as the electrode-skin in•
terface in all cases. The electrode paddles were held against 
the chest by a mechanical holding device that ensured a 
constant electrode paddle position and a constant electrode 
paddle pressure against the chest. This fibrillation-defibril•
lation sequence was repeated at 3 minute intervals, with the 
shock energy decreased in 20 J decrements: 160 J, 140 J, 
and so forth. When a shock failed to defibrillate, the energy 
was immediately increased by 10 J and the shock was re•
peated. If necessary, another shock, !OJ higher, was quickly 
given. 
The defibrillation threshold was defined as the lowest 
energy shock resulting in defibrillation; its reproducibility 
was ensured by immediately repeating the determination at 
the last two energy levels, starting at the previous highest 
energy level that failed to defibrillate and then immediately 
raising the shock energy to the previous successful level. 
Babbs et al. (4,5) showed that such fibrillation-defibrillation 
episodes were well tolerated by anesthetized dogs and di.d 
not in themselves cause blood gas changes or other phYSI•
ologic abnormalities. 
All shocks were administered using 8 cm diameter elec•
trode paddles and a Mennen-Greatbatch Cardiosentinal di•
rect current defibrillator, which delivers a damped sinusoidal 
waveform. The nominal delivered energy dial settings on 
the defibrillator were checked for accuracy before the study 
by discharging the defibrillator into a Dynatech Nevada 
defibrillator analyzer (model PEl 3100A). 
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After determination of control defibrillation threshold, 
lidocaine or bretylium was administered and defibrillation 
threshold was redetermined every 30 minutes for 2 hours. 
Lidocaine. To achieve a wide range of serum lidocaine 
levels and to correlate these levels with changes in defi•
brillation energy requirements we varied the initial bolus 
dose and subsequent rate of lidocaine infusion. An initial 
group of 16 chloralose-anesthetized dogs received low dose 
lidocaine: an intravenous bolus dose of 4 mg/kg, followed 
by an intravenous infusion of 0.1 mg/kg per min for the 
first hour and 0.2 mg/kg per min for the second hour. This 
dose was chosen to yield serum lidocaine levels in the low 
therapeutic range. In another group of six chloralose-anes•
thetized dogs, we administered high dose lidocaine: an ini•
tial 10 mg/kg intravenous bolus, followed by intravenous 
infusions of 0.3 mg/kg per min for the first hour and 0.6 
mg/kg per min for the second hour. This was done to de•
liberately achieve serum concentrations in the high thera•
peutic and toxic ranges. In nine pentobarbital-anesthetized 
dogs an intermediate lidocaine dosage schedule was used: 
a bolus dose of 4 mg/kg, followed by infusion rates of 0.2 
mg/kg per min (first hour) and 0.4 mg/kg per min (second 
hour). This different dose was selected to achieve a wider 
spectrum of increasing lidocaine concentrations from the 
therapeutic to the toxic range. while decreasing the total 
number of animals required to achieve this spectrum ('If 
different serum levels. We subsequent! y found that this in•
termediate dose lidocaine schedule yielded lidocaine levels 
that even after only 30 minutes of infusion were in the high 
therapeutic to toxic range. Therefore, we studied two ad•
ditional dogs using a very low dose lidocaine schedule: an 
initial bolus of 2 mg/kg, followed by an infusion rate of 
0.1 mg/kg per min for 30 minutes, at which point defibril•
lation threshold was remeasured. This was intended to yield 
lidocaine concentrations in the low therapeutic range. 
Plasma lidocaine concentrations were determined using 
a homogeneous enzyme immunoassay, which correlates well 
with measurements by gas liquid chromatography (6). This 
assay does not determine metabolites of lidocaine (6,7). 
Bretylium. Both chloralose- and pentobarbital-anesthe•
tized dogs (n = 10 and n = 10, respectively) received an 
initial intravenous bolus dose ofbretylium tosylate, 5 mg/kg 
intravenously, and this dose was repeated 1 hour later. De•
terminations of plasma or myocardial bretylium levels were 
not available to us at the time of this study, despite attempts 
to obtain such determinations. 
Additional Studies 
Mechanisms of lidocaine-pentobarbital interactions. 
In our preliminary studies (8) we found that the effect of 
lidocaine on defibrillation threshold was much greater in 
pentobarbital-anesthetized dogs than in chloralose-anesthe-
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tized dogs, an effect that was not explained by differences 
in serum lidocaine levels, We hypothesized that the mech•
anism of this apparent interaction between lidocaine and the 
barbiturate might be in the known but complex effects of 
barbiturate anesthesia on sympathetic and parasympathetic 
activity (9,10), We therefore sought to mimic such effects 
by administering lidocaine to chloralose-anesthetized dogs, 
determining defibrillation threshold, then undertaking ad•
ditional interventions and redetermining defibrillation 
threshold, If any of these additional interventions were the 
mechanism of the lidocaine-pentobarbital intervention, the 
defibrillation threshold in chloralose-anesthetized dogs re•
ceiving the additional intervention should have risen mark•
edly, simulating the effect of lidocaine in the barbiturate•
anesthetized dogs, 
Role of beta-receptor activation or blockade, First, we 
evaluated the possibility that the interaction might involve 
beta-adrenergic receptor activation or beta-adrenergic re•
ceptor blockade, In two dogs anesthetized with chloralose, 
we determined control defibrillation threshold, administered 
lidocaine according to the high dose protocol and redeter•
mined defibrillation threshold after 1 hour of lidocaine 
administration, With the lidocaine infusion continuing, we 
then added an intravenous infusion of the beta-adrenergic 
receptor agonist isoproterenol to increase the heart rate by 
at least 25%, After 15 minutes of isoproterenol administra•
tion, we redetermined defibrillation threshold. This dem•
onstrated the effect of beta-adrenergic receptor activation. 
Then with isoproterenol and lidocaine still being infused, 
we administered the beta-adrenergic receptor antagonist pro•
pranolol (2 mg intravenously); complete beta-adrenergic re•
ceptor blockade was first verified by a propranolol-induced 
decrease in heart rate to pre-isoproterenol levels, We then 
discontinued the isoproterenol infusion and waited an ad•
ditional 15 minutes for heart rate and blood pressure to 
restabilize at a level reflecting the effect of the beta-adre•
nergic receptor blockade, We then redetermined defibril•
lation threshold, This indicated the effect of beta-adrenergic 
receptor blockade, 
Role of alpha-adrenergic receptor activation or block•
ade, Second, we evaluated the possibility that the pento•
barbital-lidocaine interaction might involve alpha-adrener•
gic receptor activation or blockade, In two additional dogs 
anesthetized with chloralose, after 1 hour of high dose lid 
ocaine administration and determination of its effect on de•
fibrillation threshold, we added the alpha-adrenergic recep•
tor agonist phenylephrine, at a rate of 0.15 mg/min 
intravenously, to increase the systolic arterial pressure by 
at least 25%. After 15 minutes of phenylephrine and lido•
caine administration we redetermined defibrillation thresh•
old. This demonstrated the effect of alpha-adrenergic re•
ceptor activation. In six chloralose-anesthetized dogs we 
determined the effect of the alpha-antagonist phentolamine. 
In these six chloralose-anesthetized dogs we administered 
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high dose lidocaine for 1 hour and determined its effect on 
defibrillation threshold. We then administered phentolamine 
at 0.25 to 0.5 mg/min to reduce the systolic arterial pressure 
by at least 25%. After 15 minutes of phentolamine and 
lidocaine administration, we redetermined the defibrillation 
threshold. This indicated the effect of the alpha-adrenergic 
receptor blockade on defibrillation threshold of chloralose•
anesthetized dogs receiving lidocaine. To be sure that the 
observed effect of phentolamine plus lidocaine on defibril•
lation threshold was not simply a nonspecific effect of phen•
tolamine completely unrelated to the anesthesia, we also 
administered this drug to two pentobarbital-anesthetized dogs 
receiving high dose lidocaine (0.6 mg/kg per min) to cause 
a 25% decrease in systolic blood pressure, and then rede•
termined defibrillation threshold. 
Role of cholinergic or anticholinergic effect of pento•
barbital. Third, we evaluated the possibility that the lido•
caine-pentobarbital interaction might be explained by a cho•
linergic or anticholinergic effect of the barbiturate. In three 
chloralose-anesthetized dogs we exposed the vagi by blunt 
dissection bilaterally. A midcervical vagotomy was per•
formed and electrodes were attached to the distal vagi. Stim•
ulation was performed using a Grass stimulator that deliv•
ered 1.5 mA of current at 20 Hz, with 4 ms pulses. The 
end point was a decrease in heart rate of at least 25%. 
Defibrillation threshold was then redetermined. In two ad•
ditional chloralose-anesthetized dogs we administered high 
dose lidocaine and determined defibrillation threshold after 
1 hour. With lidocaine still being infused, we then admin•
istered atropine, 2 mg intravenously; cholinergic blockade 
was verified by a heart rate increase of at least 25%. We 
then redetermined defibrillation threshold. 
Role of drug effect on transthoracic impedance. Finally, 
we examined the possibility that the effect of lidocaine and 
pentobarbital on defibrillation threshold might be related to 
an effect of either or both of these drugs on transthoracic 
impedance. If impedance was markedly reduced by these 
drugs, less energy would be required to achieve the minimal 
current needed to defibrillate; thus, defibrillation threshold 
would be reduced. To evaluate this we anesthetized two 
dogs with Innovar Vet (fentanyl droperidol), 0.13 mllkg. 
Shocks of 70 J were given to these animals using a Hewlett•
Packard model 78670A defibrillator, which annotates peak 
current and transthoracic impedance after each shock. Each 
animal received an initial pre-control shock; data from this 
first shock were discarded, because it has been shown that 
transthoracic impedance tends to fall with repeated shocks, 
but particularly after the first shock (11,12). We then ad•
ministered two control shocks separated by 5 minutes and 
followed by an infusion of pentobarbital, 15 mg/kg intra•
venously. After 15 minutes, two more shocks were given 
5 minutes apart. Then the animals received lidocaine ac•
cording to the intermediate dose pentobarbital procotol: a 4 
mg/kg intravenous bolus, followed by a lidocaine infusion, 
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0.2 mg/kg per min for 30 minutes, and two final shocks 5 
minutes apart. After each shock transthoracic impedance 
was noted. 
Statistical analysis. Multiple comparisons of drug ef•
fects on hemodynamic variables and defibrillation thresholds 
were made by analysis of variance for a repeated measures 
design. Paired comparisons (in the studies of the lidocaine•
pentobarbital interaction mechanism) were done using Stu•
dent's t test. All data are expressed as mean ± I standard 
deviation (SD). 
Results 
Lidocaine (Table 1). Sixteen dogs received chloralose 
anesthesia and low dose lidocaine, six received chloralose 
and high dose lidocaine and nine received pentobarbital and 
intermediate dose lidocaine. The serum lidocaine concen•
tration achieved by lidocaine administration in the three 
JACC Vol 7, No 2 
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lidocaine protocols used are shown in Figure I. The effects 
of lidocaine on left ventricular and aortic pressures, heart 
rate and defibrillation threshold are given in Table I. The 
defibrillation thresholds varied markedly in individual ani•
mals, ranging from 20 to 200 1. The standard deviation 
within each group was large and there was considerable 
variation among groups. For comparative purposes we 
therefore also normalized the defibrillation thresholds by 
dividing each individual dog's defibrillation threshold de•
termined during drug administration by that dog's control 
threshold. A similar procedure was used by Babbs et al. 
(4). These data are shown in Figures 2 and 3. 
Lidocaine caused no significant hemodynamic changes 
in any of the three dosage schedules used. Maximal serum 
lidocaine concentrations achieved were 3.8 ± 0.8 JLg/ml 
(± SD) (chloralose anesthesia, low dose lidocaine admin•
istration), 15.0 ± 3.6 JLg/ml (pentobarbital anesthesia, in-
Table 1. Effect of Intravenous Lidocaine on Hemodynamics and Defibrillation Threshold 
Lidocaine 
Control 30 Min 60 Min 90 Min 120 Min 
A. Chloralose AnestheSia, Low Dose Lidocaine Infusion Protocol (n = 16) 
Heart rate (beats/min) 196 ± 28 192 ± 25 184 ± 21 188 ± 30 191 ± 30 
Systolic arterial pressure 167 ± 31 148 ± 24 146 ± 22 149 ± 20 153 ± 23 
(mmHg) 
Diastolic arterial pressure 104 ± 21 96 ± 16 95 ± 13 96 ± 14 98 ± 18 
(mmHg) 
Left ventncular end- 7 ± 2 7 ± 3 8 ± 4 8 ± 3 7 ± 2 
diastolic pressure 
(mmHg) 
Serum lidocaine (JLg/ml) 0.1 ± 0.1 2.2 ± 0.7 2.4 ± 0.7 3.4 ± 0.9 3.8 ± 0.8 
Defibrillation threshold (1) 79 ± 30 82 ± 32 84 ± 38 90 ± 46 90 ± 49 
B. Chloralose AnestheSia, High Dose Lidocaine Infusion Protocol (n = 6) 
Heart rate (beats/min) 190 ± 31 175 ± 33 156 ± 28 137 ± 21 
Systolic arterial pressure 174 ± 8 159 ± 12 151 ± 5 147 ± 3 
(mmHg) 
Diastolic arterial pressure 100 ± 8 99 ± 14 101 ± 5 98 ± 3 
(mmHg) 
Left ventricular end- 7 ± 1 8 ± 8 ± 2 9 ± 3 
diastolic pressure 
(mmHg) 
Serum lidocaine (JLg/ml) 0.0 ± 01 8.0 ± 2.1 9.2 ± 1.0 14.1 ± 2.4 16.6 ± 4.9* 
Defibrillation threshold (J) 119 ± 50 130 ± 59 120 ± 83 143 ± 121 
C. Pentobarbital Anesthesia, Intennediate Dose Lidocaine Infusion Protocol (n = 9) 
Heart rate (beats/min) 180 ± 18 178 ± 14 171 ± 20 164 ± 25 164 ± 29 
Systolic arterial pressure 153 ± 22 150 ± 21 143 ± 14 132 ± 14 129 ± 13 
(mm Hg) 
Diastolic arterial pressure 112 ± 14 108 ± 16 106 ± 12 98 ± 12 96 ± 14 
(mm Hg) 
Left ventricular end- 11 ± 4 12 ± 3 13 ± 3 14 ± 3 14 ± 3 
diastolic pressure 
(mm Hg) 
Serum lidocaine (JLg/ml) 0.2 ± 0.2 6.2 ± 1.5 7.6 ± 2.5 12.8 ± 2.9 150 ± 3.6 
Defibrillation threshold (1) 49 ± 20 64 ± 27 68 ± 37 77 ± 32 78 ± 36 
*Only two dogs in this subgroup survived at 120 minutes. All data are expressed as mean ± SO. 
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Figure 1. Serum lidocame concentrations achieved by the three 
infusion protocols used. Triangles = chloralo~e anesthesia, high 
dose lidocaine; circles = chloralose anesthesia, low dose lido•
caine; squares = pentobarbital anesthesia, intermediate dose 
lidocaine. 
termediate dose administration) and 16.6 ± 4.9 jLg/ml 
(chloralose anesthesia, high dose lidocaine administration) 
(Fig. 1). Only two of the six animals given high dose lid•
ocaine completed the full 2 hour protocol; in the four others, 
the heart could be defibrillated but resuscitation became 
impossible during the fibrillation-defibrillation sequences 
while lidocaine was being administered, probably because 
the serum lidocaine concentration in this group was well 
into the toxic range. 
Pentobarbital-anesthetized dogs. Lidocaine caused the 
normalized defibrillation threshold to rise significantly in 
pentobarbital-anesthetized dogs; this effect was seen as early 
as 30 minutes (Fig. 2). Normalized defibrillation threshold 
Figure 2. Effect of lidocaine on defibrillation threshold (Off) of 
dogs anesthetized with chloralose or pentobarbital. For compari•
son, the effect of repeated fibrillatIOn-defibrillation sequences on 
defibrillation threshold of anesthetized dogs receiving no lidocaine 
is also shown: open circles = chloralose anesthesia, no lidocaine 
(n = lO)(data from Kerberet al. [13]); closed circles = chloralose 
anesthesia, low do~e lidocaine (n= 16); closed triangles = chlor•
alose anesthesia, high dose lidocaine (n = 6); open squares = 
pentobarbital anesthesia, no lidocaine (n = 5) (data from Babb, 
et al. [5]); closed squares = pentobarbital anesthesia, intermediate 
dose lidocaine (n = 9). SD = standard deviation. Asterisk In•
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Figure 3. Effect of bretylium on defibrillation threshold (DFf) 
of dog, ane,thetized with chloralose or pentobarbital. For com•
pariwn, the effect of repeated fibrillation-defibrillation sequences 
on defibrillation threshold of anesthetized dogs receiving no bre•
tylium is also shown: open circles = chloralose anesthesia, no 
bretylium (n = 10) (data from Kerber et al. [13]); closed circles 
= chloralose anesthe~ia, bretylium (n = 10); open squares = 
pentobarbital anesthesia, no bretylium (n = 5) (data from Babbs 
et al. [5]); closed squares = pentobarbital anesthesia, bretylium 
(n = 10). 
reached a maximum of 1.6 ± 0.5 at 90 and 120 minutes 
of lidocaine infusion. In the two additional pentobarbital•
anesthetized dogs that received a low dose lidocaine infu•
sion, the serum lidocaine levels after 30 minutes were 2.2 
and 1.2 jLg/ml; normalized defibrillation thresholds at that 
time were 1.2 (20 J increase) and 1.3 (30 J increase). 
Chloralose-anesthetized dogs. When lidocaine was ad•
ministered to chloralose-anesthetized dogs, the normalized 
defibrillation threshold showed only a lesser rise to 1.2 ± 
0.4 (p = NS; Fig. 2). These differing responses of defi•
brillation threshold to lidocaine, depending on the anesthetic 
used, were not explained by differing serum lidocaine lev•
els. For example, although the maximal serum lidocaine 
levels achieved at 90 to 120 minutes in the chloralose•
anesthetized, high dose lidocaine group were similar to the 
serum levels achieved in the pentobarbital-anesthetized group, 
the defibrillation thresholds rose markedly in the pentobar•
bital group and only minimally in the chloralose group. The 
rise of defibrillation threshold in the pentobarbital-anesthe•
tized dogs paralleled the rising serum levels of lidocaine. 
Bretylium (Table 2). Twenty dogs received bretylium. 
The drug caused no significant hemodynamic alterations, 
although systolic and diastolic blood pressures tended to 
increase in the pentobarbital-anesthetized dogs that received 
bretylium. The alterations in actual or normalized (Fig. 3) 
defibrillation thresholds when bretylium was administered 
to either chloralose- or pentobarbital-anesthetized dogs did 
not achieve statistical significance. 
Mechanism of Lidocaine-Pentobarbital Interaction 
We studied additional dogs in our effort to determine the 
mechanism of the apparent interaction between lidocaine 
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and pentobarbital that resulted in the significant increases 
in defibrillation thresholds described earlier. 
Effects of beta-adrenergic receptor activation and 
blockade. In two chloralose-anesthetized dogs the mean 
defibrillation threshold after I hour of lidocaine adminis•
tration was 70 J. With isoproterenol plus lidocaine, heart 
rate increased from an average of 130 to 175 beats/min and 
blood pressure changed from 125/95 to 150/82 mm Hg. The 
mean defibrillation threshold was 60 J. When propranolol 
was administered in addition to isoproterenol plus lidocaine, 
heart rate returned to pre-isoproterenol levels (130 beats/min). 
After isoproterenol was discontinued, heart rate decreased 
further to 102 beats/min and blood pressure decreased to 
90/68 mm Hg and defibrillation threshold fell further with 
propranolol, to 55 J. 
Effects of alpha-adrenergic receptor activation and 
blockade. In two chloralose-anesthetized dogs the mean 
defibrillation threshold was 90 J after 1 hour of lidocaine 
administration and remained unchanged after phenylephrine 
was added and lidocaine continued. Systolic blood pressure 
increased from 128 to 187 mm Hg and diastolic blood pres•
sure from 100 to 150 mm Hg. Heart rate decreased from 
115 to 98 beats/min. 
In six chloralose-anesthetized dogs the mean defibrilla•
tion threshold was 107 ± 38 J after 1 hour of lidocaine 
administration and rose to 121 ± 58 J (p < 0.05) after 
phentolamine was added and lidocaine continued. Five of 
these six animals showed a rise in defibrillation threshold 
lACC Vol 7, No 2 
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of 10,35,40,50 and 70 J, respectively, with phentolamine 
and lidocaine; in one dog defibrillation threshold did not 
change. Systolic arterial pressure decreased from 144 ± 35 
to 112 ± 27 mm Hg with phentolamine and lidocaine 
(p < 0.05) and diastolic pressure decreased from 105 ± 
29 to 82 ± 18 mm Hg (p < 0.05); heart rate increased 
from 124 ± 19 to 142 ± 22 beats/min (p < 0.05). In 
contrast, the two pentobarbital-anesthetized dogs that also 
received lidocaine and phentolamine showed a mean defi•
brillation threshold energy decrease from 120 to 115 J; sys•
tolic pressure decreased from 158 to 120 mm Hg and dia•
stolic pressure from 125 to 95 mm Hg. 
Effects of cholinergic stimulation and blockade. In 
three chloralose-anesthetized dogs the mean defibrillation 
threshold was 70 J after 1 hour of lidocaine administration 
and rose to 77 J during bilateral vagal stimulation and con•
tinued lidocaine (defibrillation threshold rose in one animal, 
fell in one and did not change in one). Heart rate decreased 
in all three dogs from a mean of 133 beats/min to 85 beats/min. 
In two chloralose-anesthetized dogs the defibrillation 
threshold was 90 J after 1 hour of lidocaine administration 
and did not change after atropine was added and lidocaine 
continued. Heart rate increased from 82 to 165 beats/min. 
Effects of pentobarbital and lidocaine on transthor•
acic impedance. The control transthoracic impedance in 
the two dogs averaged 57.5 n. After pentobarbital, imped•
ance changed minimally to 56 n, a 3% decrease. After the 
lidocaine bolus and intermediate dose lidocaine, there was 
Table 2. Effect of Intravenous Bretylium on Hemodynamics and Defibrillation Threshold 
Bretylium 
Control 30 Min 60 Min 90 Min 120 Min 
A. Chloralose Anesthesia (n = 10) 
Heart rate (beats/mm) 185 ± 18 168 ± 30 167 ± 32 167 ± 38 154 ± 28 
Systolic arterial 174 ± 21 163 ± 26 ISS ± 22 157 ± 18 158 ± 28 
pressure (mm Hg) 
Diastolic arterial 115 ± 25 107 ± 35 101 ± 20 107 ± 20 109 ± 30 
pressure (mm Hg) 
Left ventncular end- 8 ± 3 10 ± 4 II ± 8 13 ± II II ± 5 
diastolic pressure 
(mm Hg) 
Defibrillation 60 ± 54 55 ± 41 57 ± 40 54 ± 46 58 ± 52 
threshold (1) 
B. Pentobarbital Anesthesia (n = 10) 
Heart rate (beats/min) 176 ± 16 164 ± 14 158 ± 16 166 ± 18 162 ± 25 
Systolic arterial ISO ± 23 160 ± 30 162 ± 31 174 ± 28 182 ± 25 
pressure (mm Hg) 
Diastolic arterial 104 ± 18 106 ± 22 113 ± 32 123 ± 30 130 ± 19 
pressure (mm Hg) 
Left ventncular end- 9 ± 5 10 ± 4 10 ± 4 12 ± 4 12 ± 4 
diastolic pres,ure 
(mmHg) 
Defibrillation 59 ± 31 50 ± 27 50 ± 27 49 ± 25 44 ± 31 
threshold (1) 
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a further small decrease to 53.5 fl, 7% less than the control 
value. 
Discussion 
The major findings of this study were: I) in this exper•
imental model lidocaine increased the transthoracic defi•
brillation energy requirements but this effect was, in part, 
anesthesia-related, occurring more noticeably in barbiturate•
anesthetized dogs than in chloralose-anesthetized dogs; 2) 
the increase in defibrillation energy requirements caused by 
lidocaine paralleled the rising serum levels of this drug in 
the barbiturate-anesthetized dogs; and 3) bretylium had no 
significant effect on the energy requirements for transthor•
acic defibrillation. 
Defibrillation threshold. Babbs et al. (4,5) demon•
strated that the defibrillation threshold, a measure of the 
energy requirements for transthoracic defibrillation, was re•
producible and that pentobarbital-anesthetized animals had 
defibrillation energy requirements similar to those of non•
anesthetized animals. We (13) have previously confirmed 
that chloralose-anesthetized animals behave similarly to 
pentobarbital-anesthetized ones in this regard; with both 
anesthetic agents, defibrillation threshold tends to gradually 
decline through repeated fibrillation-defibrillation sequences 
if no intervention is undertaken (4,13). Data from these 
studies are shown in Figures 2 and 3 for purposes of com•
parison with the present study. 
Effect of lidocaine on defibrillation threshold. Babbs 
et al. (1) reported that intravenous lidocaine raised the trans•
thoracic defibrillation threshold by 50 to 100% in pento•
barbital-anesthetized dogs. No serum lidocaine levels were 
obtained in their study. We were able to reproduce the effect 
of lidocaine on defibrillation energy requirements: lidocaine 
caused a 60% rise in the transthoracic defibrillation threshold 
of the pentobarbital-anesthetized dogs we studied. But the 
effect of lidocaine was much less impressive when admin•
istered to chloralose-anesthetized animals, suggesting that 
the effect is anesthesia-related; in other words, it is in part 
produced by an interaction between lidocaine and the pen•
tobarbital anesthetic used. This suggestion is reinforced by 
our observation that the changes in defibrillation threshold 
were not simply determined by serum lidocaine levels. Lev•
els from low therapeutic to toxic ranges were deliberately 
achieved in both pentobarbital- and chloralose-anesthetized 
animals, but the marked rise in defibrillation threshold we 
saw occurred only in the pentobarbital-anesthetized dogs, 
even though serum lidocaine levels were comparable or even 
slightly higher in the chloralose-anesthetized dogs that re•
ceived high dose lidocaine. On the other hand, the noticeable 
increase in defibrillation threshold energy requirements be•
tween 60 and 90 minutes of lidocaine administration to 
pentobarbital-anesthetized dogs paralleled the increase in 
lidocaine infusion rate we selected and the serum lidocaine 
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concentration that was achieved, showing that the effect of 
the lidocaine was related to the serum lidocaine level achieved 
in the pentobarbital-anesthetized dogs. 
In the pentobarbital-anesthetized dogs the lowest serum 
lidocaine level was 6.2 ± 1.5 /Lg/ml at 30 minutes of 
intermediate dose lidocaine infusion. In humans this would 
represent a lidocaine level just in the toxic range. Could the 
pentobarbital-lidocaine effect on defibrillation energy re•
quirements we observed actually represent a toxic effect? 
In the two pentobarbital-anesthetized dogs that received very 
low dose lidocaine infusion, the levels achieved were in the 
very low therapeutic range (1.2 and 2.2 /Lg/ml); these low 
levels were associated with small increases in the normalized 
defibrillation thresholds to 1.3 and 1.2. Furthermore, two 
of the dogs receiving intermediate dose lidocaine in our 
study had serum lidocaine levels of 4.3 and 4.2 /Lg/ml after 
30 minutes of infusion, which is a mid therapeutic level in 
humans. In these two dogs the normalized defibrillation 
threshold at the corresponding point in the experiment was 
1.5 and 1.67, respectively. Thus, lidocaine increased de•
fibrillation energy requirements in pentobarbital-anesthe•
tized dogs at therapeutic levels as well as at toxic levels. A 
similar relation between lidocaine plasma concentrations 
and defibrillation energy requirements using an internal de•
fibrillation system with a trapezoidal waveform was recently 
reported by Dorian et al. (14). 
Mechanism of lidocaine-barbiturate interaction. We 
attempted to determine the mechanism of the lidocaine•
barbiturate interaction. Acute barbiturate anesthesia has 
complex cardiovascular effects including alterations in sym•
pathetic tone and parasympathetic tone (9, 10). Arterial baro•
receptor reflexes are considerably altered. The effects of 
pentobarbital are also dependent on whether the animal is 
unused to laboratory procedures and is apprehensive or ex•
cited, or both, at the time the anesthetic is given or whether 
it is trained and calm (9). We evaluated the effects of alpha•
adrenergic, beta-adrenergic and cholinergic activation and 
blockade on defibrillation threshold of chloralose-anesthe•
tized dogs receiving lidocaine. If any of these were the 
mechanism of the lidocaine-pentobarbital interaction, the 
defibrillation energy requirements in lidocaine-chloralose 
dogs receiving these additional manipulations should have 
increased markedly, mimicking the defibrillation energy re•
quirements of lidocaine-barbiturate-anesthetized dogs. In 
fact, the addition of the alpha-adrenergic receptor blocking 
agent phentolamine to lidocaine-chloralose-anesthetized dogs 
did cause a significant increase in defibrillation require•
ments, suggesting that at least part of the lidocaine-barbi•
turate interaction may be due to alpha-adrenergic receptor 
blockade induced by barbiturate anesthesia. However, the 
mean increase in defibrillation threshold observed during 
the phentolamine-lidocaine combination in chloralose-anes•
thetized dogs was only about 13%, noticeably less than the 
50 to 60% increases in defibrillation threshold seen when 
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lidocaine was administered to pentobarbital-anesthetized dogs. 
This suggests that other mechanisms besides alpha-adre•
nergic receptor blockade may be involved in the Iidocaine•
barbiturate interaction. 
We found a small decrease in transthoracic impedance 
with pentobarbital and lidocaine of approximately 7%. This 
modest decrease is consonant with the well known tendency 
of transthoracic impedance to decrease simply with repeated 
shocks (4,5,13) and probably does not reflect a specific 
effect of pentobarbital or lidocaine on impedance. Koo et 
al. (3) found no effect of bretylium on transthoracic imped•
ance in dogs. In any case, the magnitude of the impedance 
decrease we found is far too small to explain the marked 
rise in defibrillation threshold seen in lidocaine-pentobar•
bital dogs. 
One lidocaine metabolite, monoethylglycylxylidide, has 
significant antiarrhythmic activity (7). The lidocaine assay 
we used did not measure this metabolite, and we cannot 
entirely exclude a role for it in the lidocaine effect on de•
fibrillation threshold. However, Halkin et al. (15) showed 
that only small amounts of this metabolite were present in 
humans receiving an initial bolus dose of lidocaine followed 
by a continuous lidocaine infusion for 2 hours, the time 
period we studied in our animal experiments. 
Effect of bretylium on defibrillation threshold. 
Tacker et al. (2) found that 2 hours after bretylium was 
administered to pentobarbital-anesthetized dogs the defi•
brillation threshold had fallen to 80% of control. In our 
pentobarbital-anesthetized dogs the fall in defibrillation 
threshold after bretylium was somewhat less (87% of control 
at 2 hours; p = NS). Our results with chloralose-anesthe•
tized dogs receiving bretylium were similar. Because 
previous studies (4,5,13) have shown that trans•
thoracic defibrillation threshold falls simply with repeated 
fibrillation-defibrillation sequences as a result of decreasing 
transthoracic impedance (Fig. 2 and 3), it appears that bre•
tylium probably had no specific effect on energy require•
ments for electrical defibrillation; that is, the modest fall in 
defibrillation threshold we observed during bretylium 
administration was probably simply an effect of time and 
multiple defibrillations unrelated to the drug. In the study 
by Tacker et al. (2), defibrillation threshold fell abruptly 
immediately after bretylium administration, suggesting a 
specific effect of the drug, but we could not demonstrate 
any abrupt change in defibrillation threshold after bretylium 
(Fig. 3). Our results are consonant with the recent study of 
Koo et al. (3), who also found no effect of bretylium on 
defibrillation threshold. 
The dose of bretylium we administered is similar to that 
recommended in humans (16) and is pharmacologically ac•
tive. We were unable to obtain plasma or myocardial levels 
of bretylium. The plasma concentration of bretylium has 
not been correlated with the intensity of its antiarrhythmic 
action. Myocardial concentrations of bretylium can be far 
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higher than plasma levels and the electrophysiologic and 
antifibrillatory effects parallel myocardial rather than serum 
drug kinetics (16,17). 
Applications to patients. What is the relevance of these 
experimental observations to clinical practice? Tacker et al. 
(2) suggested that elevation of defibrillation threshold by 
antiarrhythmic drugs such as lidocaine might account for 
some failures to defibrillate. The pharmacologic effect of 
lidocaine we observed was small in relation to the inter•
animal variability, but in an individual subject an elevation 
of defibrillation energy requirement could cause a defibril•
lation failure at any given energy. But if the lidocaine effect 
on defibrillation energy requirements is anesthesia-related 
it may not occur at all in unanesthetized patients or in pa•
tients anesthetized with drugs other than pentobarbital. Two 
studies in humans have not found a major effect of lidocaine 
(18,19): we (18) found that there was no difference in the 
success of defibrillatory shocks given to patients who were 
or were not receiving intravenous lidocaine. However, al•
though the shocks we administered in that study were of 
relatively low energy (2001), no attempt was made to de•
termine an actual threshold energy for defibrillation in the 
patients receiving lidocaine compared with those who did 
not receive it. Thus, an effect of lidocaine on defibrillation 
energy requirements might have been overlooked if the ef•
fect was small or if any alteration in energy requirements 
occurred only at less than 200 J. However, none of the 
patients in that study were receiving pentobarbital anesthesia 
at the time of defibrillation. 
In another study of open chest defibrillation in patients 
undergoing coronary artery bypass and other procedures, 
Babbs et al. (19) specifically looked for but failed to dem•
onstrate an effect of lidocaine on defibrillation energy re•
quirements. Because they used successive shocks of I, 3, 
5, 7, lO and 20 J it is likely that even a modest effect of 
lidocaine on defibrillation energy requirements would have 
been observed. These surgical patients were, of course, 
anesthetized, but with drugs other than pentobarbital (Guinn 
GA, personal communication, 1984). Thus, on the basis of 
our experimental study and the two studies in humans re•
ported, we see no reason to recommend increases in the 
energy chosen for initial transthoracic shocks for patients 
with ventricular fibrillation who are receiving lidocaine, 
especially if they are not simultaneously receiving pento•
barbital anesthesia. 
Another relevant clinical question concerns the effects of 
lidocaine on the energy requirements for cardioversion of 
ventricular tachycardia rather than ventricular fibrillation. 
Lidocaine is often administered initially to such patients, 
and electrical cardioversion is then attempted if the arrhyth•
mia persists. Furthermore, such patients are often anesthe•
tized just before cardioversion, frequently with pentobar•
bital. Lidocaine alone or in combination with pentobarbital 
might have significant effects on the energy requirements 
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for cardioversion of ventricular tachycardia in such cases. 
This question was not addressed in our study. 
Whether defibrillation energy requirements are reduced 
in patients receiving bretylium is at present ullcertain. As 
noted, the energy-reducing effect of bretylium in our study 
was modest indeed, and could have been accounted for 
simply by the decrease in transthoracic impedance and de•
fibrillation energy requirements that is known to occur sim•
ply from repeated fibrillation-defibrillation episodes (4,5,13). 
One relevant human study is available: Haynes et al. (20) 
administered bretylium or lidocaine as initial antiarrhythmic 
drug therapy to 146 patients with ventricular fibrillation, 
and then attempted electrical defibrillation. They found no 
significant difference between the drugs; shocks resulted in 
defibrillation in 89% of the patients receiving bretylium 
(average of 2.8 shocks required) and in 93% of the patients 
receiving lidocaine (average of 2.4 shocks required). It should 
be noted, however, that the initial and subsequent shock 
energy levels were high: 320 ]. An energy-reducing effect 
of bretylium might not have been apparent when such high 
energy levels were selected. Data from low energy defi•
brillation in patients receiving bretylium are needed to de•
termine whether this drug lowers defibrillation energy re•
quirements in humans. 
We acknowledge the technical assistance of Andrew Silbiger, the criticism 
of Reynold Spector. MD and Michael Brody, PhD. who reviewed the 
manuscnpt and the secretanal assistance of Diane Phillips 
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